TRAVIS WEISZHAAR: Open Payments
NPI 1962585752 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$294 in 15 payments from 11 companies in 2025. Trend: 2023 $366 · 2024 $199 · 2025 $294
Food & beverage: $294
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 2 | $58 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| Medtronic, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Novo Nordisk Inc | 1 | $14 |
Products named: Omnipod, Auvelity, MOUNJARO, CAPLYTA, Qelbree, ROTATEQ, INTERSTIM, OTEZLA.
Industry payments across ID — which companies pay providers there.
